https://wikem.org/w/index.php?title=Flecainide&feed=atom&action=history
Flecainide - Revision history
2024-03-29T07:24:08Z
Revision history for this page on the wiki
MediaWiki 1.38.2
https://wikem.org/w/index.php?title=Flecainide&diff=229388&oldid=prev
ClaireLewis: /* References */
2019-09-22T19:49:45Z
<p><span dir="auto"><span class="autocomment">References</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:49, 22 September 2019</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l51">Line 51:</td>
<td colspan="2" class="diff-lineno">Line 51:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><references/></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><references/></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pharmacology]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pharmacology]]</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Category:Cardiology]]</ins></div></td></tr>
</table>
ClaireLewis
https://wikem.org/w/index.php?title=Flecainide&diff=104734&oldid=prev
ClaireLewis: Created page with "==Administration== *Type: Antiarrhythmic *Dosage Forms: *Routes of Administration: PO *Common Trade Names: ==Adult Dosing== *Atrial fibrillation, cardioversion ("pill-in-a-..."
2016-10-05T09:03:10Z
<p>Created page with "==Administration== *Type: Antiarrhythmic *Dosage Forms: *Routes of Administration: PO *Common Trade Names: ==Adult Dosing== *Atrial fibrillation, cardioversion ("pill-in-a-..."</p>
<p><b>New page</b></p><div>==Administration==<br />
*Type: Antiarrhythmic <br />
*Dosage Forms:<br />
*Routes of Administration: PO<br />
*Common Trade Names: <br />
<br />
==Adult Dosing==<br />
*Atrial fibrillation, cardioversion ("pill-in-a-pocket")<br />
**200-300mg PO once<br />
*Paroxysmal atrial tachycardia (prophylaxis)<br />
**50-150mg PO BID<br />
==Pediatric Dosing==<br />
*25-100 mg/m(2) PO 2-3 times per day, MAX dose 200 mg/m(2)/day<br />
==Special Populations==<br />
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C<br />
*[[Lactation risk categories|Lactation risk]]: Infant risk minimal<br />
*Renal dosing: adjustment may be required<br />
*Hepatic dosing: adjustment may be required<br />
<br />
==Contraindications==<br />
*Allergy to class/drug<br />
*Cardiogenic shock<br />
*Right bundle branch block (without pacemaker)<br />
*2nd or 3rd degree AV block (without pacemaker)<br />
<br />
==Adverse Reactions==<br />
===Serious===<br />
*Heart block, sinus node dysfunction<br />
*Torsades de pointes, ventricular tachycardia, ventricular fibrillation<br />
*Cardiac shock, cardiac arrest<br />
*New onset or worsening heart failure<br />
===Common===<br />
*Dizziness, fatigue, blurred vision<br />
*Nausea<br />
*Dyspnea<br />
<br />
==Pharmacology==<br />
*Half-life: 12-27h<br />
*Metabolism: Hepatic, CYP2D6<br />
*Excretion: <br />
<br />
==Mechanism of Action==<br />
*Class I C antiarrhythmic, Na+ channel blocker<br />
<br />
==Comments==<br />
<br />
==See Also==<br />
*[[antiarrhythmics]]<br />
<br />
==References==<br />
<references/><br />
[[Category:Pharmacology]]</div>
ClaireLewis